13C breath tests are a safe, non-invasive way of assessing nutrient digestion and absorption that can be used repeatedly in infancy and childhood. The aim of this study was to assess their value for measuring fat digestion in infants and young children with cystic fibrosis, and healthy controls whose pancreatic exocrine function is immature, and to monitor pancreatic enzyme supplementation.
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Six infants with cystic fibrosis (aged 10-18 months) and nine healthy controls (aged 6-19 months) were studied. After an overnight fast each child ingested 7 5 mg/kg 13C trioctanoin (99 atom°/O excess) followed by a known volume of milk. Breath samples were collected before and at 30 minute intervals thereafter for five hours. The 13C enrichment of expired carbon dioxide was measured by gas isotope ratio mass spectrometry.
The mean (SD) (fig 1A) . One child (g) had a late peak (300 min) which resulted in a low percentage dose recovered over five hours ( fig 1C) . The flattest curve (c) in fig lA was from the 6 month old infant. In contrast most children with cystic fibrosis had low enrichments of 13C in the breath, which gradually rose over the five hours ( fig 1B) . The mean (SD) time to, and height of the peak values for healthy children was 143-3 (79-1) min and 30 9 (11-5) delta respectively, and 240 (86 9) min and 17-3 (6-5) delta respectively for the children with cystic fibrosis. Both of these differences were significant at p<0 05. with cystic fibrosis. The mean (SD) values for the controls and children with cystic fibrosis were 24-2 (6 7) and 13-5 (5 3) respectively (p<0 01). Even when the child with cystic fibrosis with very low recovery (z) was excluded the differences remain significant (p<0 05). When the test was repeated on the children with cystic fibrosis with the addition of enzyme supplements, the mean time to the peak value shortened slightly from 240-0 (86.9) min to 195-0 (72 7) min (not significant), but there was no difference in the peak heights (17-3 (6-5) delta without and 17-5 (8&9) with enzymes). However, the mean percentage dose recovery increased from 13-5 (553) to 17'1 (6 9) -that is by 27% above untreated values (p<0 05) (fig 3) evidence that stable isotope breath tests can be used to demonstrate fat maldigestion even in young children. The differences in cumulative 13C production between the control children and those with cystic fibrosis were not as wide as those noted by Murphy et al in a comparable study of older children. 5 In that study, the mean sum of 13C production over four hours in patients and controls was 36-8%o and 176-9%o respectively, whereas in our study the values were 605%o and 122-3%o respectively. The lower cumulative 13C02 production in healthy infants compared with older children is probably related to small body size (which would become obvious if it were possible to compare percentage doses recovered in both studies) but may also reflect immaturity of pancreatic lipolytic activity.6 11 The higher production of 13C02 in infants compared with older children with cystic fibrosis may be due to some residual pancreatic function'2 and/or to a greater contribution of preduodenal lipase to fat digestion in this age group.13 14 The rate of 13CO2 production from children with cystic fibrosis was slow and still rising at the end of the test in three subjects ( fig 1B) . This has been noted in previous studies5 9 The enhanced recovery of 13C in children with cystic fibrosis who were taking enzyme supplements was less than expected when compared with fat balance studies' 4 and with earlier studies using the 13C labelled fat breath tests in adults,'5 older children,5 and in infants when the substrate was given directly into the duodenum.4 Again total intraluminal lipolysis (that is the effect of pancreatic and preduodenal lipases) was depressed less in young infants with cystic fibrosis than in older children, and the addition of pancreatic enzymes (which cannot realise their optimum activity at the low pH in the gut lumen of the child with cystic fibrosis) may not cause a large improvement in digestion. This is borne out by the lack of increase in 13C recovery with the addition of enzyme supplements to the child whose percentage dose recovered was already just within the range of the healthy control group. However, further studies on the effect of increasing doses of enzyme supplements on 13C recovery should be done.
We have ascribed the differences in 13C recovery between normal children and those with cystic fibrosis to differences in intraluminal fat digestion. We have assumed that absorption, oxidation, and carbon dioxide production rates were similar in the two groups. Histological and functional abnormalities of the intestinal mucosa in cystic fibrosis have been well documented.16 Depletion of the bile salt pool through increased faecal losses and increased production of glycine rather than taurine conjugates contribute to fat malabsorption.'7 However, as a medium chain fatty acid, the absorption of octanoic acid is dependent neither on the concentration of bile salts in the duodenum nor on mucosal integrity,18 and once absorbed it is completely oxidised.19
Because it was impractical to measure carbon dioxide production rates by indirect calorimetry in these children, we assumed a constant average value for carbon dioxide production of 5 mmo/m2/min,10 as is common practice in stable isotope studies. Carbon dioxide production is increased by significant pulmonary disease, exercise, and high dietary carbohydrate loads.20 The children were studied after an overnight fast and did not take part in any strenuous activities during the test. None of the patients with cystic fibrosis had respiratory symptoms. The debate continues over whether there is a fundamental defect in energy metabolism in children with cystic fibrosis which is unrelated to pulmonary function, infection, and nutritional status.21 22 Such a defect might result in increased carbon dioxide production. However, in a recent study of asymptomatic infants with cystic fibrosis, total energy expenditure was the same as that measured in age matched controls.23 Our assumption, therefore, that carbon dioxide production rates in infants with cystic fibrosis with no respiratory symptoms are not significantly different to those of healthy infants is justified. We concluded that the factor responsible for the changes in 13C recovery that we described was intraluminal lipolysis.
This stable isotope breath test can detect fat maldigestion and is acceptable as a safe, repeatable, non-invasive test for assessment of enzyme supplementation and other therapeutic interventions, even in infants and young children with cystic fibrosis. In this age group, however, when pancreatic exocrine function 
